CSRP2 Antibody

What is CSRP2 and why is it significant in research?

CSRP2 (Cysteine and Glycine-Rich Protein 2) is a 21-22 kDa member of the CRP family of LIM domain-containing proteins. It plays significant roles in multiple cellular processes, being expressed primarily in arterial smooth muscle, hepatic stellate cells, and fibroblasts. CSRP2 functions are regulated by growth factors, with TGF-beta upregulating and PDGF downregulating its expression. The protein contains two LIM domains (amino acids 10-61 and 119-170) featuring zinc-finger motifs, a nuclear localization signal (NLS) between amino acids 64-69, and a glycine-rich C-terminus (amino acids 176-187). CSRP2 interacts with PIAS1 and CRP2-BP to promote STAT signaling pathways, and also binds to SRF and GATA4 transcription factors to initiate smooth muscle differentiation programs . Understanding CSRP2's molecular interactions provides insights into cellular differentiation and signaling mechanisms relevant to both basic research and pathological conditions.

How do I select the appropriate CSRP2 antibody for my research application?

When selecting a CSRP2 antibody, consider these methodological criteria: 1) Determine your target species - available antibodies demonstrate varying cross-reactivity profiles with human CSRP2 sharing protein sequence identity with numerous species (Human, Bovine, Pig at 100%; Mouse, Rat at 92%; Dog at 85%) . 2) Identify your application requirements - different CSRP2 antibodies are validated for Western Blotting, ELISA, immunohistochemistry (IHC), immunofluorescence (IF), or immunocytochemistry (ICC) . 3) Consider the specific epitope region - some antibodies target amino acids 90-139, others target aa 1-193 or specific domains within the protein, affecting epitope accessibility in different experimental conditions . 4) Evaluate validation data - look for antibodies validated through knockout/knockdown testing which demonstrates true specificity as opposed to cross-reactivity . 5) Determine if you need a monoclonal (higher specificity) or polyclonal (broader epitope recognition) antibody based on your experimental goals. A thorough evaluation of these parameters will ensure selection of an appropriate CSRP2 antibody for your specific research needs.

What are the common applications for CSRP2 antibodies in research?

CSRP2 antibodies support multiple research applications with distinct methodological considerations for each: 1) Western Blotting (WB) - CSRP2 antibodies detect the protein at approximately 21 kDa under reducing conditions, requiring optimization of protein loading (typically 30μg of whole cell extract) and primary antibody concentration (1:500-1:2000 dilution range) . 2) Immunohistochemistry (IHC) - for detection in tissue sections, with protocols available for both paraffin-embedded (IHC-p) and frozen sections (IHC-fro) . 3) Immunofluorescence (IF) - used to visualize cellular localization of CSRP2, with protocols for both cell culture (IF-cc) and tissue preparations (IF-p) . 4) ELISA - for quantitative measurement of CSRP2 levels . 5) Immunocytochemistry (ICC) - for subcellular localization studies in cultured cells . Each application requires specific optimization of fixation methods, antibody concentrations, and detection systems. When studying CSRP2's role in smooth muscle differentiation or hepatic stellate cell activation, researchers typically employ combinations of these techniques to correlate protein expression with cellular phenotypes.

How do I optimize Western blot protocols for CSRP2 detection?

For optimal CSRP2 detection by Western blotting, implement this methodological approach: 1) Sample preparation - extract proteins from target cells (e.g., ME-180 or HeLa cell lines known to express CSRP2) using RIPA buffer supplemented with protease inhibitors; load 30μg of total protein per lane . 2) Electrophoresis conditions - use reducing conditions with standard SDS-PAGE (10-12% gels) to effectively separate proteins around the 21-22 kDa range where CSRP2 migrates . 3) Transfer parameters - transfer to PVDF membrane at 100V for 60-90 minutes in standard transfer buffer (25mM Tris, 192mM glycine, 20% methanol). 4) Blocking - block membranes with 5% non-fat dry milk or 1% BSA in TBST for 1 hour at room temperature . 5) Primary antibody incubation - dilute CSRP2 antibody to 1-2 μg/mL in blocking buffer and incubate overnight at 4°C . 6) Detection system - use an appropriate HRP-conjugated secondary antibody (e.g., anti-goat IgG at 1:4,000 dilution for AF6196) and ECL substrate for visualization. 7) Controls - include a loading control (β-actin) and, ideally, CSRP2 knockout/knockdown samples to confirm antibody specificity . This protocol should produce a specific band at approximately 21 kDa representing CSRP2 protein.

What cell lines and tissue samples are most appropriate for CSRP2 expression studies?

For robust CSRP2 expression studies, select experimental systems where the protein is endogenously expressed or can be manipulated: 1) Recommended cell lines - ME-180 and HeLa cervical epithelial carcinoma cell lines have been validated for CSRP2 expression and antibody testing . Vascular smooth muscle cells, hepatic stellate cells, and fibroblasts also naturally express CSRP2 and are physiologically relevant models . 2) Tissue samples - arterial tissue sections, liver (particularly in fibrotic conditions where stellate cells are activated), and fibrotic lesions are appropriate for examining endogenous CSRP2 expression . 3) Expression modulation - TGF-β treatment upregulates CSRP2 expression while PDGF treatment downregulates it, providing useful experimental conditions to validate antibody specificity through induced expression changes . 4) Species considerations - when selecting animal models, consider species conservation: human CSRP2 shares 100% identity with bovine and pig proteins, 92% with mouse and rat, and 85% with dog . 5) Genetically modified systems - CRISPR-Cas9 knockout cell lines serve as excellent negative controls for antibody validation and specificity testing . These systems provide appropriate biological contexts for investigating CSRP2 function and validating antibody performance.

How can I validate the specificity of my CSRP2 antibody?

To rigorously validate CSRP2 antibody specificity, implement this multi-faceted approach: 1) CRISPR-Cas9 knockout validation - generate CSRP2 knockout cell lines using CRISPR-Cas9 gene editing in relevant cell models (e.g., ME-180 or HeLa cells); compare antibody signal between wildtype and knockout cells across applications; complete signal loss in knockout samples confirms specificity . 2) RNAi knockdown validation - transfect cells with CSRP2-specific siRNA alongside appropriate controls (scrambled siRNA, untreated cells); verify knockdown efficiency by RT-qPCR (>70% reduction in mRNA); then perform Western blot and immunocytochemistry to confirm corresponding protein reduction . 3) Peptide competition - pre-incubate the antibody with excess immunizing peptide (e.g., synthetic peptide covering aa90-139 for ABIN6746083) before application; specific signal should be blocked by the competing peptide . 4) Cross-species reactivity testing - test antibody against samples from different species according to predicted reactivity based on sequence homology; signal strength should correlate with sequence conservation (stronger in species with higher identity) . 5) Multi-antibody validation - compare results using antibodies targeting different CSRP2 epitopes; concordant results strengthen confidence in specificity. This comprehensive validation strategy ensures antibody reliability for downstream applications.

How can CSRP2 antibodies be used to investigate protein-protein interactions?

For investigating CSRP2 protein-protein interactions, implement these advanced methodological approaches: 1) Co-immunoprecipitation (Co-IP) - use a validated CSRP2 antibody to immunoprecipitate the protein complex from cell lysates, followed by Western blotting to detect known binding partners (PIAS1, CRP2-BP, SRF, or GATA4) . Optimize lysis conditions to preserve protein complexes using mild detergents (0.5% NP-40 or Digitonin) instead of harsh RIPA buffer. 2) Proximity Ligation Assay (PLA) - combine CSRP2 antibody with antibodies against suspected interaction partners in fixed cells; if proteins are within 40nm, the oligonucleotide-conjugated secondary antibodies will generate a detectable fluorescent signal. 3) Bimolecular Fluorescence Complementation (BiFC) - though not directly using antibodies, this complementary approach can verify interactions identified by antibody-based methods. 4) Pull-down assays - use recombinant CSRP2 as bait to capture interacting proteins from cell lysates, then detect using specific antibodies. 5) ChIP-re-ChIP - for investigating CSRP2's role in transcriptional complexes with SRF and GATA4, use sequential chromatin immunoprecipitation with CSRP2 antibody followed by partner protein antibodies. These techniques provide spatial and temporal information about CSRP2's interactions that regulate smooth muscle differentiation and STAT signaling pathways.

What are the challenges in detecting post-translational modifications of CSRP2?

Detecting post-translational modifications (PTMs) of CSRP2 presents several methodological challenges requiring specialized approaches: 1) PTM-specific antibodies - standard CSRP2 antibodies may not detect or may have altered affinity for modified forms of the protein; consider using modification-specific antibodies (phospho-specific, acetylation-specific, etc.) alongside total CSRP2 antibodies for comprehensive analysis. 2) Enrichment strategies - implement phosphopeptide enrichment (TiO2, IMAC) or ubiquitinated protein enrichment before mass spectrometry analysis to increase detection sensitivity of low-abundance modified forms. 3) 2D gel electrophoresis - separate CSRP2 isoforms by isoelectric point and molecular weight to resolve PTM variants before antibody detection. 4) Mass spectrometry validation - confirm antibody-detected modifications through mass spectrometry analysis of immunoprecipitated CSRP2. 5) Biological context - consider that CSRP2's LIM domains (zinc finger motifs) are potential sites for regulatory modifications affecting protein-protein interactions; treatment with TGF-β or PDGF may alter modification patterns . 6) PTM preservation - use phosphatase inhibitors, deacetylase inhibitors, or proteasome inhibitors during sample preparation to preserve labile modifications. These approaches help overcome the technical challenges in studying how PTMs regulate CSRP2's function in smooth muscle differentiation and cellular signaling pathways.

How can I use CSRP2 antibodies in multiplexed imaging applications?

For multiplexed imaging applications with CSRP2 antibodies, implement these advanced methodological strategies: 1) Antibody panel selection - carefully select CSRP2 antibodies from different host species (rabbit, goat, mouse) to enable combination with antibodies against other targets of interest ; ensure all antibodies are validated for immunofluorescence applications. 2) Sequential immunostaining - for highly multiplexed imaging beyond 4-5 targets, employ sequential immunostaining with fluorophore inactivation or antibody stripping between rounds. 3) Spectral unmixing - when using fluorophores with overlapping emission spectra, implement spectral unmixing algorithms during image acquisition and analysis to distinguish between signals. 4) Tyramide signal amplification (TSA) - for low-abundance CSRP2 detection, use TSA systems to amplify signal while maintaining compatibility with multiplex approaches. 5) Clearing techniques - for thick tissue sections, combine CSRP2 immunostaining with tissue clearing methods (CLARITY, iDISCO, CUBIC) to enable deep tissue imaging of protein localization. 6) Colocalization analysis - quantify CSRP2 colocalization with interaction partners (SRF, GATA4) using appropriate statistical methods (Pearson's correlation, Manders' coefficient). 7) Controls - include single-stained samples for compensation controls and CSRP2 knockout samples as negative controls . These approaches enable visualization of CSRP2 in the context of multiple cellular markers, providing spatial information about its role in tissue and cellular architecture.

How do I troubleshoot weak or absent CSRP2 signal in Western blots?

When encountering weak or absent CSRP2 signal in Western blots, implement this systematic troubleshooting approach: 1) Expression verification - confirm CSRP2 expression in your sample by RT-qPCR before protein analysis; consider using TGF-β treatment to upregulate expression in appropriate cell types . 2) Protein extraction optimization - CSRP2 contains zinc-finger motifs within its LIM domains ; use lysis buffers containing zinc chelator-free protease inhibitors and avoid excessive reducing agents that might disrupt domain structure. 3) Loading amount - increase loading to 30-50μg total protein; CSRP2 is a relatively low-abundance protein at 21-22kDa . 4) Transfer efficiency - for small proteins like CSRP2, use PVDF membranes with 0.2μm pore size instead of 0.45μm; consider adding SDS (0.1%) to transfer buffer to enhance elution from gel. 5) Antibody concentration and incubation - increase primary antibody concentration (2-5μg/mL) and extend incubation to overnight at 4°C . 6) Detection sensitivity - use high-sensitivity ECL substrates or switch to fluorescent detection systems with lower background. 7) Cross-reactivity checking - verify you're examining the correct molecular weight range (21-22kDa); CSRP2 shares 79% identity with CSRP1 which could complicate interpretation. 8) Antibody functionality - validate antibody using positive control lysates from cells known to express CSRP2 (ME-180, HeLa) . This methodical approach should resolve most detection issues with CSRP2 Western blotting.

What factors might cause non-specific binding with CSRP2 antibodies and how can I minimize them?

To minimize non-specific binding with CSRP2 antibodies, address these contributing factors and implement appropriate solutions: 1) Cross-reactivity with homologous proteins - CSRP2 shares 79% amino acid identity with CSRP1 ; validate specificity using CRISPR knockout controls and select antibodies targeting unique regions rather than conserved LIM domains. 2) Blocking optimization - test multiple blocking agents (5% milk, 1-5% BSA, commercial blocking buffers) to identify optimal conditions; for polyclonal antibodies, consider adding serum from the host species to reduce background. 3) Antibody concentration - titrate primary antibody concentration to find the optimal signal-to-noise ratio; excessive antibody increases non-specific binding while insufficient antibody reduces specific signal . 4) Wash stringency - increase wash duration and number of washes with 0.1-0.3% Tween-20 in TBS/PBS; consider adding low salt (150mM NaCl) to reduce ionic interactions. 5) Secondary antibody specificity - use highly cross-adsorbed secondary antibodies specific to the host species of your CSRP2 primary antibody; pre-adsorb secondary antibodies with tissue/cell lysate from your experimental system. 6) Fixation artifacts - for immunohistochemistry/immunofluorescence, optimize fixation conditions (duration, temperature, fixative composition) as overfixation can increase background through non-specific protein crosslinking. 7) Endogenous immunoglobulin binding - when working with tissues containing endogenous immunoglobulins, use Fab fragment blocking or commercial blocking reagents specifically designed to block endogenous Ig. These strategies should significantly reduce non-specific binding while preserving specific CSRP2 detection.

How do I interpret CSRP2 expression patterns in different cellular compartments?

When analyzing CSRP2 subcellular localization patterns, consider these methodological interpretations: 1) Nuclear vs. cytoplasmic distribution - CSRP2 contains a nuclear localization signal (NLS) between amino acids 64-69 , enabling nuclear translocation; quantify nuclear/cytoplasmic ratios using appropriate imaging software to assess shuttling dynamics. 2) Stimulus-dependent localization - monitor localization changes following TGF-β treatment (which upregulates CSRP2) or PDGF treatment (which downregulates it) ; these growth factors may affect not only expression but also subcellular distribution. 3) Co-localization analysis - CSRP2 interacts with transcription factors SRF and GATA4 ; assess nuclear co-localization with these partners during differentiation processes using multi-channel imaging and colocalization statistics. 4) LIM domain interactions - the two LIM domains (aa 10-61 and 119-170) mediate protein-protein interactions; distinctive localization patterns may reflect engagement with different binding partners. 5) Cell-type specific patterns - compare localization between smooth muscle cells, hepatic stellate cells, and fibroblasts to identify tissue-specific functions. 6) Differentiation status correlation - during smooth muscle differentiation, track CSRP2 redistribution as it engages with transcriptional machinery. 7) Artifactual localization - validate patterns using multiple fixation methods and CSRP2 antibodies targeting different epitopes to rule out fixation or antibody artifacts. These interpretive approaches help connect CSRP2 localization patterns to its biological functions in cellular differentiation and signaling pathways.

How can CSRP2 antibodies be used in single-cell protein analysis techniques?

For implementing CSRP2 antibodies in single-cell protein analysis, consider these advanced methodological approaches: 1) Mass cytometry (CyTOF) - conjugate CSRP2 antibodies with rare earth metals for inclusion in multiplexed panels; particularly useful for analyzing CSRP2 expression heterogeneity across cell populations in contexts such as vascular development or fibrosis. 2) Single-cell Western blotting - apply microfluidic platforms that separate proteins from individual cells followed by in-situ immunoprobing with CSRP2 antibodies; enables correlation of CSRP2 levels with other signaling proteins at single-cell resolution. 3) Imaging mass cytometry - combine CSRP2 antibodies with tissue imaging and mass spectrometry to map protein expression with subcellular resolution in tissue contexts. 4) Proximity extension assay (PEA) - utilize paired antibodies against CSRP2 conjugated with DNA oligonucleotides that, upon proximal binding, generate quantifiable PCR products; allows highly sensitive detection from minimal sample volumes. 5) Drop-seq protein analysis - adapt CSRP2 antibodies for droplet-based single-cell proteomics workflows to correlate with transcriptomic data. 6) Validation considerations - for all single-cell applications, validate antibody performance in bulk assays before scaling to single-cell level ; confirm specificity using CRISPR knockout controls at the single-cell level. These emerging technologies enable unprecedented insights into CSRP2 expression heterogeneity and its correlation with cellular phenotypes in complex tissues.

What are the considerations for using CSRP2 antibodies in high-throughput screening applications?

When implementing CSRP2 antibodies in high-throughput screening (HTS) applications, address these methodological considerations: 1) Assay miniaturization - optimize CSRP2 antibody concentration and detection systems for microplate formats (384/1536-well); determine minimal detection limits using serial dilutions of positive control lysates (ME-180, HeLa cells) . 2) Automation compatibility - select detection methods compatible with automated liquid handling (homogeneous assays preferred over wash-intensive protocols); validate reproducibility across multiple plates and days. 3) Readout selection - for phenotypic screens, choose appropriate readouts: high-content imaging for localization, AlphaLISA/HTRF for binding interactions, or cell-based reporter assays for functional impacts on STAT signaling pathways . 4) Z-factor optimization - calculate Z-factors using CSRP2 knockout/knockdown cells as negative controls and TGF-β stimulated cells (which upregulate CSRP2) as positive controls ; aim for Z'>0.5 for robust screening. 5) Multiplexing strategy - determine compatibility of CSRP2 antibodies with multiplexed detection to simultaneously measure related pathway components; test for signal interference when combining antibodies. 6) Reference standards - develop quantitative standards for normalizing CSRP2 signals across screening plates; consider recombinant CSRP2 protein standards. 7) Data normalization - implement robust statistical methods for normalizing CSRP2 signals and identifying true hits while controlling false discovery rates. These considerations ensure reliable implementation of CSRP2 antibodies in screening campaigns investigating modulators of smooth muscle differentiation or hepatic stellate cell activation.

How can CSRP2 antibodies contribute to tissue-specific biomarker development?

For developing tissue-specific biomarkers using CSRP2 antibodies, implement these strategic methodological approaches: 1) Tissue microarray (TMA) validation - screen CSRP2 expression across diverse normal and pathological tissues using validated antibodies ; quantify staining patterns using digital pathology algorithms to identify tissue-specific signatures. 2) Multi-marker panels - develop panels combining CSRP2 with other tissue-specific markers; for vascular pathologies, combine with smooth muscle markers (αSMA, SM22α) since CSRP2 participates in smooth muscle differentiation . 3) Correlation with activation states - in liver fibrosis studies, correlate CSRP2 with hepatic stellate cell activation markers to develop staging biomarkers . 4) Sample type optimization - validate CSRP2 antibody performance across various specimen types (FFPE tissues, frozen sections, fine needle aspirates, liquid biopsies) to determine optimal diagnostic applications. 5) Analytical validation - establish precision, reproducibility, and limits of detection for CSRP2 quantification using reference standards; determine pre-analytical variables affecting CSRP2 detection (fixation time, storage conditions). 6) Clinical correlation - associate CSRP2 expression patterns with clinical outcomes to assess prognostic value; correlate with treatment response for predictive biomarker potential. 7) Multiplexed detection platforms - adapt CSRP2 antibodies to multiplexed systems (multiplexed IHC, digital spatial profiling) to develop spatially-resolved tissue signatures. These approaches facilitate development of CSRP2-based biomarkers for conditions involving vascular remodeling, fibrosis, or tissue-specific differentiation programs.